Ibandronate Sodium Tablets

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D2-25-R-0019

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

-

SourceSAM
Documents4
This procurement notice, identified as SPE2D2-25-R-0019, is issued by DLA Troop Support, a federal office responsible for providing critical supplies to military and government entities. The solicitation seeks qualified contractors to supply Ibandronate Sodium Tablets, a pharmaceutical product used primarily in the treatment of bone disorders such as osteoporosis. The procurement falls under NAICS code 325412 (Pharmaceutical Preparation Manufacturing), indicating that the requirement is for the manufacturing and delivery of finished pharmaceutical preparations. The associated Product Service Code is 6505, further specifying the focus on drugs and biologicals. The purpose of this procurement is to ensure a reliable supply of Ibandronate Sodium Tablets to meet the ongoing needs of the Department of Defense and other federal customers supported by DLA Troop Support. The scope of work likely includes the manufacture, packaging, and delivery of the tablets in accordance with federal quality standards and regulatory requirements, although specific quantities, packaging configurations, and delivery schedules would be detailed in the solicitation attachments. Key objectives of this procurement include maintaining product quality, ensuring timely delivery, and complying with all applicable pharmaceutical manufacturing regulations. Contractors are expected to demonstrate their capability to produce and supply Ibandronate Sodium Tablets that meet the required specifications. Deliverables will typically include the finished pharmaceutical product, accompanied by all necessary documentation to verify compliance with federal standards. The notice is structured as a Combined Synopsis/Solicitation, streamlining the acquisition process by combining the synopsis and solicitation phases. This approach is intended to expedite procurement and is commonly used for commercial items. The opportunity is posted on SAM.gov, with four attachments available for review, which likely contain detailed specifications, terms and conditions, and submission instructions. The contracting activity is managed by DLA Troop Support, with primary and secondary points of contact provided for contractor inquiries: Christopher Newman ([email protected], 445-737-7371) and Catherine Gilbert ([email protected], 445-737-8868). The notice was posted on June 10, 2025, with responses due by October 10, 2025. As of the current status, the notice is marked inactive. Contractors considering this opportunity should have established capabilities in pharmaceutical preparation manufacturing, a proven track record of regulatory compliance, and the ability to meet federal supply chain requirements. The procurement does not specify any set-aside requirements or special considerations in the provided information. Interested parties are encouraged to review the attachments on the SAM.gov listing for comprehensive details and to contact the designated representatives for clarification as needed. This opportunity represents a recurring federal requirement for pharmaceutical products, with consistent expectations for quality, reliability, and regulatory adherence throughout the contract lifecycle.